Clinical Trial Update: Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder [Phase 2]

View source ↗

Summary

This report notes a Phase 2 clinical trial testing a D1 dopamine receptor agonist for cognitive enhancement in individuals with schizotypal personality disorder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizotypal Personality Disorder

Drugs mentioned

• D1 agonist

Snippet

Sponsor: Larry J. Siever | Conditions: Cognitive Impairments, Schizotypal Personality Disorder | Phase 2 | Status: UNKNOWN